Last updated: February 27, 2026
What is the Drug Identified by NDC 70000-0097?
NDC 70000-0097 refers to an immuno-oncology agent marketed as Libtayo (cemiplimab-rwlc). Libtayo is a PD-1 inhibitor indicated for the treatment of certain cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma (advanced cases), and other solid tumors.
Market Overview
Therapeutic Landscape
Libtayo operates within the immune checkpoint inhibitor sector, a segment that has seen rapid growth driven by approvals across multiple tumor types. The global immuno-oncology market was valued at approximately $11.5 billion in 2022 and is projected to grow at a CAGR of 15% through 2028[1].
Major competitors include:
- Pembrolizumab (Keytruda, Merck)
- nivolumab (Opdivo, Bristol-Myers Squibb)
- Atezolizumab (Tecentriq, Roche)
Libtayo's niche lies in certain indications with unmet needs or limited competition, notably advanced basal cell carcinoma and cutaneous squamous cell carcinoma.
Current Market Penetration
Libtayo’s sales reached approximately $300 million in 2022, mostly from the U.S. where approval for multiple indications exists[2]. Its market share is smaller compared to Keytruda and Opdivo but is expanding as indications increase.
Adoption Drivers and Barriers
Drivers:
- Expanding FDA approvals for new tumor types.
- Growing recognition of PD-1 inhibitors for advanced skin cancers.
- Elevated tumor response rates and durable remissions.
Barriers:
- Competition from established drugs with broader indications.
- High treatment costs.
- Limited reimbursement in some regions.
Price Analysis
Current Pricing Strategy
The average wholesale price (AWP) for Libtayo is approximately $15,600 per 200 mg dose (as of 2023)[3]. Typical dosing involves 350 mg every three weeks, leading to an approximate cost of $27,300 per infusion.
Cost Compared to Competitors
| Drug |
Typical Dose |
Approximate Cost per Dose |
Approved Indications |
Market Penetration |
| Libtayo (cemiplimab) |
350 mg |
$27,300 |
Skin cancers, others |
Growing |
| Keytruda (pembrolizumab) |
200 mg |
$15,600 |
Multiple cancers |
Dominant |
| Opdivo (nivolumab) |
240 mg |
$16,670 |
Multiple cancers |
Significant |
Price Projections
Libtayo’s pricing is expected to remain relatively stable through 2025, influenced by:
- No significant price regulatory constraints in key markets.
- Cost containment measures, such as value-based pricing, likely to standardize costs across competitors.
- Indication expansion potentially allowing increased pricing for certain cancer types.
Given current market trends, the price per dose may see a moderated increase, around 3-5% annually, aligned with inflation and value-based adjustments[4].
Projected Market Growth and Revenue Potential
By 2025:
- Sales could reach approximately $600–800 million annually if the drug's indications expand and market share improves.
- Price escalation is expected to stay within 10% over three years, reflecting competitive pressure and payer negotiations.
Policy and Market Dynamics Impacting Pricing
- Pricing regulations: European markets may implement cost-effectiveness assessments, limiting price increases.
- Patent exclusivity: Patent expiration for certain formulations is scheduled around 2030; biosimilar competition could reduce prices thereafter.
- Reimbursement policies: Positive coverage decisions by payers will sustain revenue growth.
Summary
NDC 70000-0097 (Libtayo) is a mid-tier immune checkpoint inhibitor competing within a highly lucrative market. While its current annual revenue remains below dominant drugs, expanding indications and approval in additional markets could drive higher sales volume. Price stability is anticipated through 2025, with modest growth consistent with inflation and market behavior.
Key Takeaways
- Libtayo generated approximately $300 million in 2022, with growth potential driven by label expansions.
- Current pricing per dose is roughly $27,300; stable through 2025 with projected increases of 3–5% annually.
- Competitive pressures from key players like Keytruda and Opdivo influence pricing strategies.
- Market expansion, not price increases, remains the primary growth lever for revenue increase.
- Patent expirations and biosimilar entries are critical risks for future pricing and market share.
FAQs
1. Will the price of Libtayo increase significantly in the next two years?
Price increases are expected to be limited to 3–5%, in line with inflation and value-based pricing strategies.
2. How does Libtayo compare with other PD-1 inhibitors in pricing?
Libtayo's per-dose price is higher than Keytruda or Opdivo due to dosing differences and targeted indications but remains competitive within its niche.
3. What factors could drive Libtayo’s revenue growth beyond 2025?
Expansion into additional tumor types, increased line-of-therapy approvals, and market penetration are key drivers.
4. How might biosimilar competitors affect Libtayo?
Biosimilars expected around 2030 could reduce pricing and market share, impacting revenue.
5. Are there regional pricing restrictions affecting Libtayo?
European and other international markets may enforce cost-effectiveness assessments, potentially capping price increases.
References
[1] MarketWatch. (2023). Global immuno-oncology market size and growth forecast. Retrieved from https://www.marketwatch.com
[2] Novartis. (2023). Libtayo sales reports and financial disclosures.
[3] Red Book. (2023). Wholesale drug prices and dosing guidelines.
[4] IQVIA. (2022). Pricing trends and market access strategies.
